# Intrathecal Double Checkpoint Inhibition

> **NCT05598853** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Zurich** · enrollment: 26 (estimated)

## Conditions studied

- Leptomeningeal Metastasis
- Non-small Cell Lung Cancer Stage IV
- Melanoma Stage IV

## Interventions

- **DRUG:** intrathecal nivolumab and intrathecal ipilimumab

## Key facts

- **NCT ID:** NCT05598853
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-25
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598853, "Intrathecal Double Checkpoint Inhibition". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05598853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*